Healthcare Whitepaper and Newsletter

Our multidimensional, purposeful, and credible market analysis will help accelerate your business growth and overcome challenges with a practical approach.
ASCO Reveals: Increasing Options for Relapse/ Refractory Patients in Haematological Malignancies Whitepaper
In Focus
ASCO Reveals: Increasing Options for Relapse/ Refractory Patients in Haematological Malignancies
Immunotherapies, a potentially life-saving therapy, have benefitted several patients suffering from cancer help to achieve complete remission that many other times, traditional chemotherapies fail to deliver. Thus, cellular immunotherapies for refractory/relapsed Haematological Malignancies patients are a novel treatment approach that helps to eliminate the chances of remission in malignancy patients. Through the whitepaper, DelveInsight brings to its clients and readers the gradual shift in the way the cures and treatment regimens for cancer are being preferred.
Read More
Raynauds phenomenon Newsletter
Raynaud's phenomenon
Raynaud’s phenomenon (RP) is a condition that results in discoloration of fingers or toes caused by episodic vasospasm and ischemia of the extremities in response to cold or emotional stimuli. Usually, the condition is visible in distal digits; however, the discoloration can also be seen in the nose, ears and tongue. With no cure at hand, Raynaud’s phenomenon has symptomatic treatment options available in the market. Gain more insights into the Raynaud’s phenomenon, its causes, symptoms, epidemiological insights and available therapeutic options through DelveInsight’s newsletter.
Go to Newsletter
Paroxysmal Nocturnal Hemoglobinuria Whitepaper
Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired disease that leads to the destruction of red blood cells, blood clots, and an impaired bone marrow caused due to the mutation in the PIGA (Phosphatidylinositol glycan class A) gene. DelveInsight's brings another addition to its Newsletter Series focusing on a life-threatening disease of the blood. The newsletter provides a brief introduction of the indication - Paroxysmal Nocturnal Hemoglobinuria, its epidemiological analysis, preponderance in different populations, treatment approaches, unmet needs in the market, and upcoming therapies in the future.
Go to Newsletter
Fibrodysplasia Ossificans Progressiva Whitepaper
Fibrodysplasia Ossificans Progressiva
Fibrodysplasia Ossificans Progressiva (FOP) is a rare disorder that results in gradual ossification of the connective tissues and muscle tissues, such as ligaments and tendons. They are replaced by bone (ossified), forming extra-skeletal or heterotopic bone that constrains movement. Being a rare disorder, and no diagnostics indicator and overall lack of understanding delays the treatment of the disease.However, through its newsletter series, DelveInsight, aims to increase awareness about the indication, its underlying causes, etiology, signs and symptoms.
Go to Newsletter
ASCO Reveals: Increasing Options for Relapse/ Refractory Patients in Haematological Malignancies Whitepaper
ASCO Reveals: Increasing Options for Relapse/ Refractory Patients in Haematological Malignancies
Immunotherapies, a potentially life-saving therapy, have benefitted several patients suffering from cancer help to achieve complete remission that many other times, traditional chemotherapies fail to deliver. Thus, cellular immunotherapies for refractory/relapsed Haematological Malignancies patients are a novel treatment approach that helps to eliminate the chances of remission in malignancy patients. Through the whitepaper, DelveInsight brings to its clients and readers the gradual shift in the way the cures and treatment regimens for cancer are being preferred.
Go to Newsletter
Evolution of Precision Medicine in Oncology Whitepaper
Evolution of Precision Medicine in Oncology
Past decades have witnessed a shift in the focus of researchers and pharma companies towards tailoring the treatment approach and regiment cancer patients are administered. Unlike traditional chemotherapies, Precision Medicine is targeted therapies that target the genetic mutations and locations of cancer. Through the whitepaper, DelveInsight brings to its clients and readers the journey of one of the most looked upon and emerging therapies in the oncology that is curated precisely to offer best-class treatment - Precision Medicine.
Go to Newsletter
COVID-19 Whitepaper
COVID-19
Over the last months, the world has faced one of the most unexpected challenges in the form of a novel coronavirus, SARS-CoV-2, infection. Through the whitepaper, DelveInsight aims to make its clients and users aware of the exact scenario of the novel coronavirus SARS-CoV-2 and the disease COVID-19. The whitepaper is a detailed description of SARS-CoV-2 virus, its morphology and pathophysiology, and the trends of the patients affected, most prevalent symptoms, as well as understand the asymptomatic traits.
Go to Newsletter
Generalized Myasthenia Gravis Newsletter
Generalized Myasthenia Gravis
Myasthenia Gravis is a chronic autoimmune neuromuscular disease responsible for weakness in the skeletal muscles, including the muscles of arms and legs, leading to breathing difficulty and mobility issues. When the muscles affected are from multiple muscle groups throughout the body, it is called generalized myasthenia gravis (gMG).With a higher diagnosed prevalence of generalized Myasthenia Gravis in the United States of approximately 32,188 cases, gMG has an equal prevalent ratio in males and females.
Go to Newsletter
Gaucher Disease Newsletter
Gaucher Disease
The most common lysosomal disease, Gaucher Disease is a result of lack of sufficient glucocerebrosidase (GCase), an enzyme required for the break-down of glucocerebroside thus causing a build-up in areas like the spleen, liver, and bone marrow. With an equal prevalence in males and females, the overall frequency of Gaucher Disease is approximately 1 in 50,000 to 1 in 100,000 live births. The newsletter by DelveInsight offers a crisp overview of the indication, its subtypes and symptoms.
Go to Newsletter
Duchenne Muscular Dystrophy Newsletter
Duchenne Muscular Dystrophy
A genetic disorder, Duchenne Muscular Dystrophy (DMD), is a progressive form of muscular dystrophy with a higher preponderance in males; however, in some rare cases, it can occur in females too. As per DelveInsight, the total prevalent population of Duchenne Muscular Dystrophy in the 7MM was found to be 31,386, whereas, total diagnosed prevalent population was found to be 26,678 in 2017. The newsletter will help the readers and clients to gain a perspective on the latest trends in the Duchenne Muscular Dystrophy Market, its epidemiology and the role of mutations that form the underlying cause of the disease.
Go to Newsletter
Cutaneous Lupus Erythematosus Newsletter
Cutaneous Lupus Erythematosus
An autoimmune disease in which the immune system attacks its healthy skin, Cutaneous Lupus Erythematosus, belongs to the family of Lupus Erythematosus (LE). Through the newsletter, DelveInsight brings to light about a condition that had a prevalence of 327,569 in the US alone in 2017. The newsletter provides an overview of the indication, symptoms, causes, and etiology. It also put forward the historical epidemiological trends listing its prevalence and incidence, with the 11-year forecast.
Go to Newsletter
Complex Regional Pain Syndrome Newsletter
Complex Regional Pain Syndrome
A chronic pain condition, Complex Regional Pain Syndrome (CRPS) often affects one limb and is believed to be caused by injury, or malfunction of, the peripheral and central nervous systems. DelveInsight, through its newsletter series, aims for increased awareness about the indication, its underlying causes, etiology, symptoms, and risk factors among its readers. The newsletter is a brief introduction of the indication - Complex Regional Pain Syndrome, with its epidemiological analysis, preponderance, treatment approaches, unmet needs in the market, and upcoming therapies in the horizon.
Go to Newsletter
Fragile X Syndrome Newsletter
Fragile X Syndrome
Fragile X Syndrome is a syndrome, which results in intellectual disabilities as well as affects the physical characteristics of the people, and is a result of mutation associated with the gene FMR1. DelveInsight's newsletter series brings to light an overview of Fragile X syndrome, underlying causes, risk factors, etiology, and symptoms. The newsletter provides a brief scenario of the prevalence and incidence of the disease, present treatment approaches and the therapies and drugs in the pipeline for the disease.
Go to Newsletter
Pompe disease Newsletter
Pompe disease
An autosomal metabolic disorder – Pompe disease results in deterioration of organs and tissues as a consequence of excess accumulation of glycogen in muscle and nerve cells throughout the body. Also called Glycogen Storage disease type II, Pompe disease affects around 5,000 to 10,000 people worldwide, with an equal preponderance in Males and females.
Go to Newsletter
Impact of BREXIT on Pharma Space Newsletter
Impact of BREXIT on Pharma Space
BREXIT, the 'EXIT' of 'BRITAIN' from 'EUROPEAN UNION', shook the whole world when the United Kingdom voted in the favor of leaving the EU. This was mainly done to access greater control of the country's borders as well as economy, which also led to major impact on various countries that have conducted business and trade within the UK borders. After the vote, the country has been wrought in uncertainty related to political, regulatory and economic scenario.
Go to Newsletter
An Abundance Of Rare Newsletter
An Abundance Of Rare
Though appear rare, rare diseases are far from being rare. With over 7,000 rare disease affecting millions worldwide, Rare disease pose a huge burden on the global healthcare system, affecting the quality of lives of patients. There is still a lack of understanding in the abundance of the rare diseases prevalent globally and treatment approaches that are being adapted. DelveInsight, with its new newsletter series, aims to put forward enriching content related to various rare diseases for a crystal-clear picture of the rare disease, their therapies, and market trends.
Go to Newsletter
Cancer Globally (Vol. 1, Issue 1) Newsletter
Cancer Globally (Vol. 1, Issue 1)
Cancer has gripped the human society in its clutches in such a way that there has been many advancements to treat the same, but with little success. The full extent of the disease can only be measured by the population that it has plagued, and how varied it has become over the course of years. Cancer by Numbers provide us with the degree of devastation it has incurred among various populations, and provides us with a better idea on the level of progress needed to eradicate this morbid indication. It also sheds light on the blockbuster drugs along with potential therapies for the cancer.
Go to Newsletter
Cancer in The United States(Vol 1, Issue 2) Newsletter
Cancer in The United States(Vol 1, Issue 2)
US Cancer Statistics show that more than half a million suffer from this disease, which is the second leading cause of death in the country. The newsletter Cancer in the US substantiates the increasing incidence and prevalence of major cancer sub-types in the American patient population, drawing conclusions related to the seriousness of the matter. This edition further points out to the top selling cancer drugs in the country and how new and innovative therapies are being researched to limit the devastating impact of this debilitating disease. Read on to know more
Go to Newsletter